These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 26784539)

  • 21. Delivery of foreign cytotoxic T lymphocyte epitopes to tumor tissues for effective antitumor immunotherapy against pre-established solid tumors in mice.
    Kavunja HW; Lang S; Sungsuwan S; Yin Z; Huang X
    Cancer Immunol Immunother; 2017 Apr; 66(4):451-460. PubMed ID: 28011995
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Selective cytotoxic T-lymphocyte targeting of tumor immune escape variants.
    van Hall T; Wolpert EZ; van Veelen P; Laban S; van der Veer M; Roseboom M; Bres S; Grufman P; de Ru A; Meiring H; de Jong A; Franken K; Teixeira A; Valentijn R; Drijfhout JW; Koning F; Camps M; Ossendorp F; Kärre K; Ljunggren HG; Melief CJ; Offringa R
    Nat Med; 2006 Apr; 12(4):417-24. PubMed ID: 16550190
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Phosphorylated peptides can be transported by TAP molecules, presented by class I MHC molecules, and recognized by phosphopeptide-specific CTL.
    Andersen MH; Bonfill JE; Neisig A; Arsequell G; Sondergaard I; Valencia G; Neefjes J; Zeuthen J; Elliott T; Haurum JS
    J Immunol; 1999 Oct; 163(7):3812-8. PubMed ID: 10490979
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Non-mutated neoantigens, TEIPP, as new targets for cancer immunotherapies].
    Vouilloz A; Serre L
    Med Sci (Paris); 2020 Jan; 36(1):83-86. PubMed ID: 32014105
    [No Abstract]   [Full Text] [Related]  

  • 25. Combining the antigen processing components TAP and Tapasin elicits enhanced tumor-free survival.
    Lou Y; Basha G; Seipp RP; Cai B; Chen SS; Moise AR; Jeffries AP; Gopaul RS; Vitalis TZ; Jefferies WA
    Clin Cancer Res; 2008 Mar; 14(5):1494-501. PubMed ID: 18316574
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Bystander elimination of antigen loss variants in established tumors.
    Spiotto MT; Rowley DA; Schreiber H
    Nat Med; 2004 Mar; 10(3):294-8. PubMed ID: 14981514
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A specific cytotoxic T-lymphocyte epitope presentation system for antitumor immunity.
    Wu Y; Liu C; Sun M; Shen H; Guo D; Gao B
    Int J Cancer; 2010 May; 126(10):2373-86. PubMed ID: 19810094
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Inhibition of serine-peptidase activity enhances the generation of a survivin-derived HLA-A2-presented CTL epitope in colon-carcinoma cells.
    Preta G; Marescotti D; Fortini C; Carcoforo P; Castelli C; Masucci M; Gavioli R
    Scand J Immunol; 2008 Dec; 68(6):579-88. PubMed ID: 19000094
    [TBL] [Abstract][Full Text] [Related]  

  • 29. MHC class I antigen processing and presenting machinery: organization, function, and defects in tumor cells.
    Leone P; Shin EC; Perosa F; Vacca A; Dammacco F; Racanelli V
    J Natl Cancer Inst; 2013 Aug; 105(16):1172-87. PubMed ID: 23852952
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Importance of TAP-independent processing pathways.
    Oliveira CC; van Hall T
    Mol Immunol; 2013 Sep; 55(2):113-6. PubMed ID: 23183105
    [TBL] [Abstract][Full Text] [Related]  

  • 31. HLA-A2-restricted CTL epitopes of a novel lung cancer-associated cancer testis antigen, cell division cycle associated 1, can induce tumor-reactive CTL.
    Harao M; Hirata S; Irie A; Senju S; Nakatsura T; Komori H; Ikuta Y; Yokomine K; Imai K; Inoue M; Harada K; Mori T; Tsunoda T; Nakatsuru S; Daigo Y; Nomori H; Nakamura Y; Baba H; Nishimura Y
    Int J Cancer; 2008 Dec; 123(11):2616-25. PubMed ID: 18770861
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Multidrug resistance-associated protein 3 is a tumor rejection antigen recognized by HLA-A2402-restricted cytotoxic T lymphocytes.
    Yamada A; Kawano K; Koga M; Matsumoto T; Itoh K
    Cancer Res; 2001 Sep; 61(17):6459-66. PubMed ID: 11522641
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The mutation in the ATP-binding region of JAK1, identified in human uterine leiomyosarcomas, results in defective interferon-gamma inducibility of TAP1 and LMP2.
    Hayashi T; Kobayashi Y; Kohsaka S; Sano K
    Oncogene; 2006 Jul; 25(29):4016-26. PubMed ID: 16474838
    [TBL] [Abstract][Full Text] [Related]  

  • 34. In vivo programming of tumor antigen-specific T lymphocytes from pluripotent stem cells to promote cancer immunosurveillance.
    Lei F; Zhao B; Haque R; Xiong X; Budgeon L; Christensen ND; Wu Y; Song J
    Cancer Res; 2011 Jul; 71(14):4742-7. PubMed ID: 21628492
    [TBL] [Abstract][Full Text] [Related]  

  • 35. T cell recognition of HLA-A2 restricted tumor antigens is impaired by the oncogene HER2.
    Mimura K; Ando T; Poschke I; Mougiakakos D; Johansson CC; Ichikawa J; Okita R; Nishimura MI; Handke D; Krug N; Choudhury A; Seliger B; Kiessling R
    Int J Cancer; 2011 Jan; 128(2):390-401. PubMed ID: 20715101
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Identification of a novel HLA-A2-restricted cytotoxic T lymphocyte epitope from cancer-testis antigen PLAC1 in breast cancer.
    Liu W; Zhai M; Wu Z; Qi Y; Wu Y; Dai C; Sun M; Li L; Gao Y
    Amino Acids; 2012 Jun; 42(6):2257-65. PubMed ID: 21710262
    [TBL] [Abstract][Full Text] [Related]  

  • 37. T cells specific for a TAP-independent self-peptide remain naïve in tumor-bearing mice and are fully exploitable for therapy.
    Doorduijn EM; Sluijter M; Marijt KA; Querido BJ; van der Burg SH; van Hall T
    Oncoimmunology; 2018; 7(3):e1382793. PubMed ID: 29399388
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Role of TAP-1 and/or TAP-2 antigen presentation defects in tumorigenicity of mouse melanoma.
    Agrawal S; Reemtsma K; Bagiella E; Oluwole SF; Braunstein NS
    Cell Immunol; 2004 Apr; 228(2):130-7. PubMed ID: 15219464
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Increased tumorigenicity, but unchanged immunogenicity, of transporter for antigen presentation 1-deficient tumors.
    Qin Z; Harders C; Cao X; Huber C; Blankenstein T; Seliger B
    Cancer Res; 2002 May; 62(10):2856-60. PubMed ID: 12019164
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A single amino acid variation within an immunodominant AKR/Gross MuLV cytotoxic T-lymphocyte epitope leads to a loss in immunogenicity.
    Kim V; Green WR
    Viral Immunol; 1998; 11(4):197-213. PubMed ID: 10189187
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.